PROF.DR. ERKAN YILMAZ    
Name : ERKAN
Surname : YILMAZ
E-Mail : eyilmaz@ankara.edu.tr
Phone Number : 03125961032/2546
Title : PROF.DR.
Unit : GRADUATE SCHOOL OF BIOTECHNOLOGY
Department : Basic Biotechnology
Personal Information

Erkan YILMAZ PhD


ORCID: https://orcid.org/0000-0001-7355-3878

ResearcherID: http://www.researcherid.com/rid/O-1592-2014

Google Scholar: https://scholar.google.com.tr/citations?hl=tr&user=AeQNsn4AAAAJ

Education

Degree

Program

University

Year

Undergraduate

Biology

Ankara University

1997

Masters of Science

Graduate School of  Health Sciences

Ankara University

2000

Doctorate

Graduate School of  natural and Applied Sciences 

Gazi University

2004

Associate Professorship

Molecular and Cellular Biology 

CoHE (Counsel of Higher Education)

2011

Professor

Basic Biotechnology

Ankara University

2019

 

Experience

Position

Institution

Year

Research Assistant

Ankara University Medical School

1999-2002

Research Assistant & Postdoctoral Fellow

Harvard University

2002-2006

Postdoctoral Fellow

Ankara University Biotechnology Institute

2006-2010

Assistant Professor

Ankara University Faculty of Science Dept. Biology

2010-2012

Associate professor

Ankara University Biotechnology Institute

2012-2019

Professor

Ankara University Biotechnology Institute

2019-


Awards:  

 

Member of Scientific societies: Turkish Society of Hematology,  Turkish Biochemical Society

 

Award : 

Erkan YILMAZ, TÜBA-The Young Scientists Award Programme (GEBİP) 2010.

 


Courses


Course

400100801150

Advanced  Biotechnologic Techniques

 

400100801160

400100801170

Molecular Cell Biology 

Masters and Doctorate

400100710141

Molecular Biology Criterian Articles

Masters and Doctorate


Publications 

A1.      Öztop, S., Işik, A., Güner, G., Gürdal, H., Karabulut, E., Yilmaz, E., Akyol, A. Class III β-tubulin expression in colorectal neoplasms is a potential predictive biomarker for paclitaxel response (2019) Anticancer Research, 39 (2), pp. 655-662. Cited 1 time. 

 

A2.      Farzani, T.A., Hanifehnezhad, A., Földes, K., Ergünay, K., Yilmaz, E., Ali, H.H.M., Ozkul, A. Co-delivery effect of CD24 on the immunogenicity and lethal challenge protection of a DNA vector expressing nucleocapsid protein of crimean congo hemorrhagic fever virus (2019) Viruses, 11 (1), art. no. 75, . Cited 2 times. 

 

A3.      Eylem, C.C., Yilmaz, M., Derkus, B., Nemutlu, E., Camci, C.B., Yilmaz, E., Turkoglu, M.A., Aytac, B., Ozyurt, N., Emregul, E. Untargeted multi-omic analysis of colorectal cancer-specific exosomes reveals joint pathways of colorectal cancer in both clinical samples and cell culture (2019) Cancer Letters, .  

 

A4.      Yilmaz, A.D., Yazicioglu, D., Tüzüner Öncül, A.M., Yilmaz, E., Ereş, G. Vitamin D receptor gene polymorphisms (Apa1 and Taq1) in temporomandibular joint internal derangement/osteoarthritis in a group of Turkish patients (2018) Molecular Biology Reports, 45 (6), pp. 1839-1848.  

 

A5.      Yilmaz, E. Endoplasmic reticulum stress and obesity (2017) Advances in Experimental Medicine and Biology, 960, pp. 261-276. Cited 12 times. 

 

A6.      Özerkan, D., Özsoy, N., Yılmaz, E. Vitamin D and melatonin protect the cell’s viability and ameliorate the CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines (2014) Cytotechnology, 67 (6), pp. 995-1002. Cited 6 times. 

 

A7.      Özenoǧlu, S., Aydoǧdu, G., Dinçsoy, A.B., Taghidizaj, A.A., Derici, K., Yilmaz, E., Aras, S., Cansaran-Duman, D. Evaluation of the impact on different types of human cancer cell of lichen secondary compounds [Liken sekonder bileşiklerinin farkli insan kanser hücre tipleri üzerine antikanserojenik etkisi] (2013) Turk Hijyen ve Deneysel Biyoloji Dergisi, 70 (4), pp. 215-226. Cited 5 times. 

 

A8.      Torun, D., Deda, G., Ertem, M., Uysal, Z., Yılmaz, E., Akar, N. A novel protein C inhibitor gene mutation in pediatric stroke patients after bone marrow transplantation (2013) Molecular Biology Reports, 40 (9), pp. 5465-5468.  

 

A9.      Karabiyik, A., Yilmaz, E., Güleç, S., Haznedaroǧlu, I., Akar, N. The dual diverse dynamic reversible effects of ankaferd blood stopper on EPCR and PAI-1 inside vascular endothelial cells with and without LPS challenge [Lipopolisakkarit varli{dotless}ǧi{dotless} ve yokluǧunda vasküler endotelyal hücrelerde endotelyal protein C reseptörü ve plazminojen aktivatör İnhibitör-1 üzerinde ankaferd'in geri dönüşümlü İkili karşi{dotless}t etkileri] (2012) Turkish Journal of Hematology, 29 (4), pp. 361-366. Cited 18 times. 

 

A10.   Karabiyik, A., Yilmaz, E., Eǧin, Y., Akar, N. The effects of endothelial protein C receptor gene polymorphisms on the plasma sEPCR level in venous thrombosis patients [Endotelyal protein C reseptör geni polimorfizmlerinin venöz trombozlu olgularda sEPCR üzerindeki etkisi] (2012) Turkish Journal of Hematology, 29 (1), pp. 55-62. Cited 5 times. 

 

A11.   Yilmaz, E., Güleç, S., Torun, D., Haznedaroǧlu, I.C., Akar, N. The effects of Ankaferd® blood stopper on transcription factors in HUVEC and the erythrocyte protein profile [Ankaferd® Kanama Durdurucunun HUVEC'lerde transkripsiyon faktörleri ve eritrosit protein profili üzerine etkisi] (2011) Turkish Journal of Hematology, 28 (4), pp. 276-285. Cited 26 times. 

 

A12.   Torun, D., Yilmaz, E., Akar, E., Akar, N. Role of ZIP14 (SLC39A14) gene histidine rich regions in neural tube defects (2011) Egyptian Journal of Medical Human Genetics, 12 (2), pp. 135-137. 

 

A13.   Karabiyik, A., Güleç, S., Yilmaz, E., Haznedaroglu, I., Akar, N. Reversible protease-activated receptor 1 downregulation mediated by ankaferd blood stopper inducible with lipopolysaccharides inside the human umbilical vein endothelial cells (2011) Clinical and Applied Thrombosis/Hemostasis, 17 (6), pp. E165-E170. Cited 16 times. 

 

A14.   Torun, D., Yilmaz, E., Atay, A., Kürekçi, E., Akar, N. Two new mutations at ERGIC-53 gene in a Turkish family (2011) Clinical and Applied Thrombosis/Hemostasis, 17 (3), pp. 248-250. Cited 1 time. 

 

A15.   Adigüzel, Y., Yilmaz, E., Akar, N. Effect of eNOS and ET-1 polymorphisms in thromboangiitis obliterans (2010) Clinical and Applied Thrombosis/Hemostasis, 16 (1), pp. 103-106. Cited 12 times. 

 

A16.   Yilmaz, E., Berberoglu, M., Akar, N. Relationship between functional promoter polymorphism in the XBP1 Gene (-116C/G) and obesity (2010) Clinical and Applied Thrombosis/Hemostasis, 16 (1), pp. 99-102. Cited 6 times. 

 

A17.   Yilmaz, E., Akar, R., Eker, S.T., Deda, G., Adiguzel, Y., Akar, N. Relationship between functional promoter polymorphism in the XBP1 gene (-116C/G) and atherosclerosis, ischemic stroke and hyperhomocysteinemia (2010) Molecular Biology Reports, 37 (1), pp. 269-272. Cited 11 times. 

 

A18.   Houcher, B., Bourouba, R., Djabi, F., Yilmaz, E., Eǧin, Y., Akar, N. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and cystathionine β-synthase genes as a risk factor for neural tube defects in Sétif, Algeria (2009) Pediatric Neurosurgery, 45 (6), pp. 472-477. Cited 14 times. 

 

A19.   Oguzulgen IK, Yilmaz E, Demirtas S, Erkekol FO, Ekim N, Demir N, Numanoglu N, Ozel D, Ulu A, Akar N. The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism (2009) Clinical and Applied Thrombosis/Hemostasis, Feb;15(1):73-7. Cited 11 times. 

 

A20.   Ozcan, U., Ozcan, L., Yilmaz, E., Düvel, K., Sahin, M., Manning, B.D., Hotamisligil, G.S. Loss of the Tuberous Sclerosis Complex Tumor Suppressors Triggers the Unfolded Protein Response to Regulate Insulin Signaling and Apoptosis (2008) Molecular Cell, 29 (5), pp. 541-551. Cited 321 times. 

 

A21.   Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R.O., Görgün, C.Z., Hotamisligil, G.S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes (2006) Science, 313 (5790), pp. 1137-1140. Cited 1648 times. 

 

A22.   Ulu, A., Yilmaz, E., Akar, E., Akar, N. Factor V A4070G (His1299Arg) mutation in Turkish pediatric patients with thrombosis (2005) Turkish Journal of Haematology, 22 (4), pp. 173-178. Cited 2 times. 

 

A23.   Özcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N.N., Özdelen, E., Tuncman, G., Görgün, C., Glimcher, L.H., Hotamisligil, G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes (2004) Science, 306 (5695), pp. 457-461. Cited 2447 times. 

 

A24.   Yilmaz, E., Akar, E., Akar, N. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thromboembolic patients with and without prothrombin 20210 G-A (2004) Turkish Journal of Haematology, 21 (2), pp. 83-86. Cited 10 times. 

 

A25.   Ulu, A., Yilmaz, E., Akar, E., Akar, N. Homozygosity for the HR2 haplotype: Is it a risk factor for thrombosis? (2003) Turkish Journal of Haematology, 20 (4), pp. 213-215. Cited 2 times. 

 

A26.   Tekin, M., Duman, T., Boǧoçlu, G., Incesulu, A., Çomak, E., Fitoz, S., Yilmaz, E., IIhan, I., Akar, N. Frequency of mtDNA A1555G and A7445G mutations among children with prelingual deafness in Turkey (2003) European Journal of Pediatrics, 162 (3), pp. 154-158. Cited 59 times. 

 

A27.   Akar, N., Yilmaz, E., Akar, E. Coexistence of two prothrombotic mutations, factor V 1691 G-A and prothrombin 20210 G-A, and the risk of thrombosis in Turkish population (2003) Turkish Journal of Haematology, 20 (1), pp. 31-33. Cited 3 times. 

 

A28.   Atalay, S., Akar, N., Tutar, H.E., Yilmaz, E. Factor V 1691 G-A mutation in children with intracardiac thrombosis: A prospective study (2002) Acta Paediatrica, International Journal of Paediatrics, 91 (2), pp. 168-171. Cited 14 times. 

 

A29.   Yilmaz, E., Akar, E., Sözüöz, A., Akar, N. Frequency of FV 1299 His-Arg (A4070G) in Turkish Cypriots (2001) Turkish Journal of Haematology, 18 (4), pp. 243-244. Cited 6 times. 

 

A30.   Akar, N., Akar, E., Yilmaz, E., Deda, G. Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation (2001) Journal of Child Neurology, 16 (4), pp. 294-295. Cited 28 times. 

 

A31.   Avcu, F., Akar, E., Demirkiliç, U., Yilmaz, E., Akar, N., Yalçin, A. The Role of Prothrombotic Mutations in Patients with Buerger's Disease (2000) Thrombosis Research, 100 (3), pp. 143-147. Cited 39 times. 

 

A32.   Akar, N., Yilmaz, E., Akar, E., Deda, G., Sipahi, T. Factor V (His 1299 Arg) in young Turkish patients with cerebral infarct (2000) Haemostasis, 30 (3), pp. 118-122. Cited 16 times. 

 

A33.   Akar, N., Yilmaz, E., Akar, E., Avcu, F., Yalçin, A., Cin, S. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A (2000) Thrombosis Research, 97 (4), pp. 227-230. Cited 47 times. 

 

A34.   Akar, N., Akar, E., Yilmaz, E. Factor V (His 1299 Arg) in Turkish patients with venous thromboembolism [2] (2000) American Journal of Hematology, 63 (2), pp. 102-103. Cited 27 times. 

 

A35.   Akar, N., Akar, E., Yilmaz, E. Coexistence of factor V 1691 G-A and factor V 4070 A-G mutation in Turkish thromboembolic patients [2] (2000) American Journal of Hematology, 65 (1), p. 88. Cited 7 times. 

 

A36.   Akar, N., Kemahli, S., Deda, G., Akar, E., Yilmaz, E., Uysal, Z., Cin, S. Multiple cerebral emboli in a homozygous β-thalassaemia patient due to factor V 1299 (His-Arg) 4070 A-G mutation (2000) Turkish Journal of Haematology, 17 (3), pp. 133-136. Cited 2 times.